Novartis’s $1.4B Tourmaline Acquisition Brings Heart Drug That Could Rival Novo Nordisk, CSL Meds
Novartis is getting Tourmaline Bio’s pacibekitug, a Phase 3-ready antibody drug in development for atherosclerotic…
Novartis’s $1.4B Tourmaline Acquisition Brings Heart Drug That Could Rival Novo Nordisk, CSL Meds
Novartis is getting Tourmaline Bio’s pacibekitug, a Phase 3-ready antibody drug in development for atherosclerotic cardiovascular disease (ASCVD). Tourmaline licensed pacibekitug from Pfizer, which remains eligible for milestone payments tied to the progress of the drug. The post Novartis’s $1.4B Tourmaline Acquisition Brings Heart Drug That Could Rival Novo Nordisk, CSL Meds appeared first on…
Health Costs Associated with Pregnancy, Childbirth, and Infant Care
This analysis examines the health costs associated with pregnancy, childbirth, post-partum care, and infancy. It finds that health costs associated with pregnancy, childbirth, and post-partum care average a total of $20,416, including $2,743 in out-of-pocket expenses, for women enrolled in employer plans.
The Most Powerful Tool in Healthcare Marketing: A Patient’s Voice
These stories don’t just influence individual decisions; they have the power to shift perceptions, drive treatment adoption, and reignite purpose across entire organizations. The post The Most Powerful Tool in Healthcare Marketing: A Patient’s Voice appeared first on MedCity News.
From Hospital to Home Without the Headaches: How Technology Can Smooth the Transition
Here are three things healthcare leaders should consider for improving the DME process to make the hospital-to-home experience more efficient and less stressful for all stakeholders. The post From Hospital to Home Without the Headaches: How Technology Can Smooth the Transition appeared first on MedCity News.
In the Fallout From Trump’s Health Funding Cuts, States Face Tough Budget Decisions
Patients begin lining up before dawn at Operation Border Health, an annual five-day health clinic in Texas’ Rio Grande Valley. Many residents in this predominantly Latino and Hispanic region spanning the Mexican border lack insurance, making the health fair a major source of free medical care in South Texas for more than 25 years. Until…
Instead of Selling, Some Rural Hospitals Band Together To Survive
BOWMAN, N.D. — Retta Jacobi stepped onto a metal platform that lifted her to an entrance on the side of a custom-designed semitrailer. Once inside, she lay down on a platform that technicians slid into an MRI machine. Jacobi hoped the scan would help pinpoint the source of the pain in her shoulders. The mobile…
Judge Advances Particle Health’s Antitrust Lawsuit Against Epic
A federal judge has allowed key claims in Particle Health’s antitrust lawsuit against Epic to move forward, marking the first time such allegations against the EHR giant have gotten this far. The case centers on Epic’s alleged use of its influence over the Carequality data exchange to block Particle’s access to patient records and stifle…
Takeda Is Waking Up the Narcolepsy Market With First-in-Class Drug, But Alkermes Is on Its Heels
Takeda Pharmaceutical’s oveporexton is designed to treat the root cause of narcolepsy. Statistically significant Phase 3 results for the twice daily pill were presented Monday during the World Sleep 2025 Congress in Singapore. The post Takeda Is Waking Up the Narcolepsy Market With First-in-Class Drug, But Alkermes Is on Its Heels appeared first on MedCity…
WeightWatchers Introduces New Menopause Program
WeightWatchers’ new menopause program provides support from menopause-trained clinicians, along with workshops, fitness guidance and access to prescriptions when needed. The post WeightWatchers Introduces New Menopause Program appeared first on MedCity News.
Summit Lung Cancer Drug Falls Short on Key Survival Goal in Global Study, Putting FDA Approval in Doubt
Despite achieving statistically signficant improvement in progression-free survival in North American and European patients, Summit’s drug ivonescimab fell short of the other Phase 3 goal measuring overall survival. It’s the first Phase 3 readout for an emerging class of bispecific antibodies that treat cancer by blocking two targets, PD-1 and VEGF. The post Summit Lung…
